Dovitinib (TKI-258) in RTK-Driven Cancer Assays
2026-09-25
Dovitinib (TKI-258) offers a practical way to test how multitarget RTK blockade changes signaling and cell survival in cancer models. This guide connects pathway-focused bench workflows with gastric-cancer response stratification while clearly separating preclinical hypotheses from clinical evidence.
Angiotensin I: From Peptide to Translational Signal
2026-09-24
Explore how Angiotensin I can help researchers interrogate renin–angiotensin system biology, design stronger cardiovascular experiments, and distinguish mechanistic evidence from analytical uncertainty.
TBST Workflows for Clearer Antibody Assays
2026-09-24
Use TBST to control background in antibody-based workflows, from Western blots to cell imaging, without mistaking cleaner detection for proof of mechanism. This guide connects practical buffer choices to uPAR–uPA cancer-invasion research and offers optimization steps for more interpretable results.
EZ Cap™ EGFP mRNA (5-moUTP) Lab Guide
2026-09-23
This scenario-based guide explains how EZ Cap™ EGFP mRNA (5-moUTP), SKU R1016, can help researchers separate transfection performance from cell viability, proliferation, and cytotoxicity effects. It combines practical handling guidance with evidence-based interpretation of capped, chemically modified reporter mRNA and recent delivery research.
Oteseconazole (VT-1161) Candida Assay Guide
2026-09-23
Build a practical, species-resolved workflow around Oteseconazole, a selective tetrazole CYP51 inhibitor for Candida research. This guide combines microbroth screening, fluconazole-resistant Candida testing, fungicidal follow-up, and troubleshooting for insolubility and endpoint variation.
GPC3-HSP70 mRNA Nanovaccine for HCC
2026-09-22
The reference study developed an mRNA nanovaccine encoding tandem GPC3127–136 cytotoxic T-lymphocyte epitopes fused to HSP70 and delivered it with the tumor-targeting peptide SP94-GGG-K18. In preclinical experiments, combining this construct with anti-PD-L1 therapy strengthened antigen-specific T-cell responses and antitumor activity, while also highlighting important manufacturing and translational questions for mRNA vaccine development.
AM 281: A Mechanistic Guide to CB1–GLT-1
2026-09-21
AM 281 is a selective CB1 cannabinoid receptor antagonist for mapping how endocannabinoid signaling affects astrocytic GLT-1, excitotoxicity, and cognition. This article translates recent TBI findings into practical assay decisions while defining the limits of cross-model interpretation.
In Vitro Drug Response Evaluation in Cancer
2026-09-21
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell killing and considering their timing, the study offers a more informative framework for interpreting drug responses and designing in vitro cancer experiments.
5X Protein Loading Buffer (Reducing) Guide
2026-09-20
5X Protein Loading Buffer (Reducing) supports denaturing, reducing protein sample preparation before conventional SDS-PAGE electrophoresis. It is appropriate for molecular-weight-based separation, but not for preserving native complexes, enzymatic activity, or non-reducing disulfide-linked species.
Fludarabine Workflow for DNA Synthesis Inhibition
2026-09-19
Build reproducible leukemia and multiple myeloma assays around Fludarabine’s intracellular conversion to F-ara-ATP, combining viability, cell-cycle, and apoptosis readouts. This workflow emphasizes solubility control, genotype-aware interpretation, and troubleshooting that distinguishes failed exposure from genuine resistance.
circRHOBTB3–NONO Axis in Metastatic Prostate Cancer
2026-09-19
The reference study identifies circRHOBTB3 as a downregulated circular RNA that restrains prostate cancer proliferation and metastasis by retaining NONO in the cytoplasm and reducing MAOA transcription. Its combination of clinical association, mechanistic RNA biology, and in vivo validation highlights a regulatory axis with potential value for metastatic prostate cancer research.
Zolmitriptan for Reproducible Cell Assays
2026-09-18
This scenario-based guide explains how to use Zolmitriptan, SKU B2261, in cell viability, proliferation, and cytotoxicity workflows without confusing receptor-mediated biology with nonspecific assay interference. It covers solvent control, concentration design, data interpretation, and practical supplier selection for reproducible serotonin receptor pharmacology.
Ceftazidime Workflow for Resistance Research
2026-09-18
Ceftazidime combines a Pseudomonas-focused phenotype assay with a practical route to studying plasmid-mediated resistance. This workflow connects susceptibility testing, gene localization, conjugation, and troubleshooting for more interpretable Gram-negative infection research.
TagH Links T6SS Control to V. cholerae Hemolysis
2026-09-17
The reference study identifies the FHA-domain protein TagH as a regulator that connects the type VI secretion system with HlyA-dependent hemolysis and virulence in Vibrio cholerae. Its genetic, molecular, and infection-model evidence indicates that TagH suppresses HlyA at both transcriptional and post-translational levels, with the FHA phosphopeptide-binding sites contributing to this control.
Belinostat (PXD101) Research Workflows
2026-09-17
Build reproducible histone deacetylase inhibition assays with Belinostat (PXD101), from dose-response profiling to histone acetylation, cell-cycle, and splicing readouts. The workflow distinguishes cytostatic effects from cell death and frames HDAC–PARP combinations as a testable research hypothesis rather than an established Belinostat indication.